Allergy and COVID-19

Acta Biomed. 2021 Nov 29;92(S7):e2021522. doi: 10.23750/abm.v92iS7.12402.

Abstract

The first cases of as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported in Wuhan, China in December 2019. The World Health Organization declared the global pandemic in March 2020. Coronavirus disease 2019 (COVID-19) showed high rates of mortality in the adult population, whereas a mild course was observed in childhood. Allergic diseases, characterized by a type-2 polarization of the immune system, were considered one of the major risk factor of severe COVID-19. Large amounts of clinical data and expert opinions have been collected since the pandemic outbreak. This review summarizes the latest insights on COVID-19 and allergy.

Publication types

  • Review

MeSH terms

  • Adult
  • COVID-19*
  • Disease Outbreaks
  • Humans
  • Hypersensitivity* / epidemiology
  • Pandemics
  • SARS-CoV-2